Wootton, Daniel G., Opara, Hyginus, Biagini, Giancarlo A., Kanjala, Maxwell K., Duparc, Stephan, Kirby, Paula L., Woessner, Mary, Neate, Colin, Nyirenda, Maggie, Blencowe, Hannah, Dube-Mbeye, Queen, Kanyok, Thomas, Ward, Stephen, Molyneux, Malcolm E., Dunyo, Sam and Winstanley, Peter. (2008) Open-label comparative clinical study of chlorproguanil−dapsone fixed dose combination (Lapdap™) alone or with three different doses of artesunate for uncomplicated plasmodium falciparum malaria. PLoS One, Vol.3 (No.3). e1779. ISSN 1932-6203

Preview

PDF WRAP_Winstanley_Open_journal.pone.0001779.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (610Kb)

Abstract

The objective of this study was to determine the appropriate dose of artesunate for use in a fixed dose combination therapy with chlorproguanil−dapsone (CPG−DDS) for the treatment of uncomplicated falciparum malaria.

Item Type:	Journal Article
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Plasmodium falciparum -- Treatment, Artemisinin, Drugs -- Dose-response relationship
Journal or Publication Title:	PLoS One
Publisher:	Public Library of Science
ISSN:	1932-6203
Date:	5 March 2008
Volume:	Vol.3
Number:	No.3
Page Range:	e1779
Identification Number:	10.1371/journal.pone.0001779
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	UNICEF, United Nations (UN), World Bank, World Health Organization (WHO), GlaxoSmithKline, Great Britain. Dept. for International Development
References:	1. World Health Organisation (2005) World Malaria Report. Geneva: World Health Organisation. Available online at: http://rbm.who.int/wmr2005/ (Last accessed 23rd December, 2006). 2. Hyde JE (2005) Drug-resistant malaria. Trends Parasitol 21: 494–498. 3. World Health Organisation (2004) Position Paper of WHO Roll Back Malaria Department on malaria treatment. Geneva: World Health Organisation. 4. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, et al. (1997) Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 91: 574–577. 5. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, et al. (2000) Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 94: 545–548. 6. Alin MH, Bjorkman A (1994) Concentration and time dependency of artemisinin efficacy against Plasmodium falciparum in vitro. Am J Trop Med Hyg 50: 771–776. 7. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ (2002) Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 46: 778–782. 8. Dutta GP, Bajpai R, Vishwakarma RA (1989) Artemisinin (qinghaosu)–a new gametocytocidal drug for malaria. Chemotherapy 35: 200–207. 9. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, et al. (2005) Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2: e330. 10. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, et al. (2006) Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 193: 1151–1159. 11. Hallett RL, Sutherland CJ, Alexander N, Ord R, Jawara M, et al. (2004) Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother 48: 3940–3943. 12. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, et al. (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347: 1654–1658. 13. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, et al. (1999) Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 60: 547–555. 14. Winstanley P (2001) Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health 6: 952–954. 15. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, et al. (2004) Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet 363: 1843–1848. 16. Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, et al. (2000) Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 181: 2023–2028. 17. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, et al. (2002) Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 360: 1136–1143. 18. World Health Organisation (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organisation. Available online at: http://www.who.int/malaria/ docs/ProtocolWHO.pdf (Last accessed 6th January, 2007). 19. Murphy S, Watkins WM, Bray PG, Lowe B, Winstanley PA, et al. (1995) Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Am J Trop Med Hyg 53: 303–305. 20. World Health Organisation (2002) Monitoring antimalarial drug resistance: report of a WHO consultation. Geneva: World Health Organisation. Available online at: http://rbm.who.int/cmc_upload/0/000/015/800/200239.pdf (Last accessed December 28th, 2006). 21. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 68: 133–139. 22. Joint United Nations Programme on HIV/AIDS (May, 2006) Report on the global AIDS epidemic 2006. Geneva: UNAIDS. Available online at: http:// www.unaids.org/en/HIV_data/2006GlobalReport/default.asp (Last accessed December 23rd, 2006). 23. Laufer MK, van Oosterhout JJ, Thesing PC, Thumba F, Zijlstra EE, et al. (2006) Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 193: 872–878. 24. Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, et al. (2003) Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents Chemother 47: 901–904. 25. Schwarz NG, Oyakhirome S, Potschke M, Glaser B, Klouwenberg PK, et al. (2005) 5-day nonobserved artesunate monotherapy for treating uncomplicated falciparum malaria in young Gabonese children. Am J Trop Med Hyg 73: 705–709. 26. Degowin RL, Eppes RB, Powell RD, Carson PE (1966) The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6- phosphate-dehydrogenase deficiency. Bull World Health Organ 35: 165–179. 27. World Health Organisation (2004) Review of the safety of chlorproguanildapsone in the treatment of uncomplicated falciparum malaria in Africa: report of a technical consultation convened by WHO. Geneva: World Health Organisation. Available online at: http://www.who.int/malaria/docs/Lap- Dap.pdf (Last accessed 23rd December, 2006).
URI:	http://wrap.warwick.ac.uk/id/eprint/36676

Request changes to a record

Actions (login required)

View Item